Navigation Links
Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Date:9/28/2007

ular disease. Clearly, the institution of endoluminal grafting represents a hallmark in the changing treatment paradigm for patients with potentially lethal and debilitating diseases of the thoracic aorta. Our team looks forward to continued research and scientific endeavors to hopefully, in the future, make inroads in the prevention of all cardiovascular diseases," continued Diethrich.

Study Details

From March 1998 to March 2006, repair of the thoracic aorta using an ELG was performed on 406 patients at the Arizona Heart Institute, including 324 patients receiving a commercially available FDA-approved implant with the remaining patients receiving investigational devices. Patient population included those eligible for open surgical repair and those with prohibitive surgical risk. The majority of treated patients had atherosclerotic aneurysms (157; 48.5%) and one quarter (82; 25.3%) had type B dissections. The remaining patients were treated for thoracic aortic pathologies including penetrating ulcers (34; 10.5%), pseudoaneurysms (26; 8%), transections (11; 3.4%), aorto- bronchial fistulas (9; 2.8%), aorto-esophageal fistulas (1; 0.3%) and embolization (4; 1.2%). One hundred cases (31.5%) were non-elective and 49 (15.1%) were ruptures. All patients received a follow-up evaluation at six months and yearly, with a follow-up range between one and 70 months (average 17 months).

The study results revealed the following:

-- Sac Size (only among aneurysm component): Preoperative aneurysm sac

size ranged from 5 to 12 centimeters, with an average size of 6.3 cm.

Sac shrinkage occurred in 65% (102 of 157) of patients. Average

postoperative sac size of 5.4 cm was noted in a mean follow-up of 20.4

months.

-- Endoleaks: Endoleak, or blood leakage around the ELG, creates

insufficient seal to the aorta wall. Four types of leaks have been

defined and range from type I (the most serious and requiring<
'/>"/>

SOURCE The Arizona Heart Institute
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email: